Extended Follow-Up Analysis of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Real-World...

Area of Science:

• Oncology
• Immunotherapy
• Clinical Trials

Background:

• Real-world data on first-line atezolizumab with chemotherapy for extensive-stage small cell lung cancer (ES-SCLC) is limited.
• Previous reports focused on short-term outcomes.

Purpose of the Study:

• To provide an updated analysis of the effectiveness and safety of first-line atezolizumab plus chemotherapy in ES-SCLC.
• To identify prognostic factors and evaluate subsequent treatment patterns.

Main Methods:

• Prospective, multicenter observational study of 100 ES-SCLC patients in Korea.
• Primary outcomes: 1-year overall survival (OS) and progression-free survival (PFS).
• Secondary outcomes: OS, objective response rate, disease control rate, second PFS, and safety.

Main Results:

• Median PFS: 6.2 months; Median OS: 17.1 months; 1-year OS rate: 62.5%.
• Favorable prognostic factors for OS: partial response, stable disease, and longer platinum-free interval.
• Brain radiotherapy improved OS in patients with brain metastases; thoracic radiotherapy and second-line treatment also improved survival.

Conclusions:

• First-line atezolizumab immunochemotherapy demonstrates sustained real-world effectiveness and safety in ES-SCLC.
• Local treatments and post-progression therapy are associated with improved survival outcomes.